Characterization and in vitro cellular activity assessment of photodynamic composite nanocarriers for gliomas treatment

IF 2.6 4区材料科学 Q3 CHEMISTRY, MULTIDISCIPLINARY Journal of Nanoparticle Research Pub Date : 2025-03-01 DOI:10.1007/s11051-025-06268-4

Yongxu Yang, Wenxiu Li, Junhong Zhou, Yang Yu, Shujie Liu, Qing Xu

{"title":"Characterization and in vitro cellular activity assessment of photodynamic composite nanocarriers for gliomas treatment","authors":"Yongxu Yang, Wenxiu Li, Junhong Zhou, Yang Yu, Shujie Liu, Qing Xu","doi":"10.1007/s11051-025-06268-4","DOIUrl":null,"url":null,"abstract":"<div><p>Glioblastoma (GBM) originates from cancerous cells of the central nervous system (CNS) in the brain and spinal cord, and is the most common malignant primary tumor in brain tumors, with a high degree of aggressiveness and resistance to treatment, accounting for 48.6% of CNS malignant tumors. Although metal–organic frameworks (MOFs) have been widely used in drug delivery, developing nanocarriers with both high stability and biocompatibility remains a significant challenge. This study developed a novel composite nano drug delivery system, PLGA-PDI@CP1@1, which combines poly(lactic-co-glycolic acid) (PLGA) and perylene diimide (PDI) with excellent fluorescence properties to effectively encapsulate MOF-based CP1. The system was further loaded with an active compound extracted from ginseng (compound 1) for the treatment of gliomas. Through in vitro cellular experiments, we found that PLGA-PDI@CP1@1 was able to inhibit the proliferation of cancer cells by suppressing the expression of the glioma proliferation-associated gene MAGED4.</p></div>","PeriodicalId":653,"journal":{"name":"Journal of Nanoparticle Research","volume":"27 3","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nanoparticle Research","FirstCategoryId":"88","ListUrlMain":"https://link.springer.com/article/10.1007/s11051-025-06268-4","RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Glioblastoma (GBM) originates from cancerous cells of the central nervous system (CNS) in the brain and spinal cord, and is the most common malignant primary tumor in brain tumors, with a high degree of aggressiveness and resistance to treatment, accounting for 48.6% of CNS malignant tumors. Although metal–organic frameworks (MOFs) have been widely used in drug delivery, developing nanocarriers with both high stability and biocompatibility remains a significant challenge. This study developed a novel composite nano drug delivery system, PLGA-PDI@CP1@1, which combines poly(lactic-co-glycolic acid) (PLGA) and perylene diimide (PDI) with excellent fluorescence properties to effectively encapsulate MOF-based CP1. The system was further loaded with an active compound extracted from ginseng (compound 1) for the treatment of gliomas. Through in vitro cellular experiments, we found that PLGA-PDI@CP1@1 was able to inhibit the proliferation of cancer cells by suppressing the expression of the glioma proliferation-associated gene MAGED4.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用于胶质瘤治疗的光动力复合纳米载体的特性和体外细胞活性评估

胶质母细胞瘤（Glioblastoma， GBM）起源于大脑和脊髓中枢神经系统（central nervous system， CNS）的癌细胞，是脑肿瘤中最常见的恶性原发肿瘤，具有高度的侵袭性和治疗耐药性，占中枢神经系统恶性肿瘤的48.6%。虽然金属有机骨架（mof）在药物递送中得到了广泛的应用，但开发具有高稳定性和生物相容性的纳米载体仍然是一个重大挑战。本研究开发了一种新型的复合纳米给药系统PLGA-PDI@CP1@1，该系统将具有优异荧光性能的聚乳酸-羟基乙酸（PLGA）和苝酰二亚胺（PDI）结合在一起，有效地封装了基于mof的CP1。该系统进一步加载了从人参中提取的用于治疗胶质瘤的活性化合物（化合物1）。通过体外细胞实验，我们发现PLGA-PDI@CP1@1能够通过抑制胶质瘤增殖相关基因MAGED4的表达来抑制癌细胞的增殖。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Nanoparticle Research 工程技术-材料科学：综合

CiteScore

4.40

自引率

4.00%

发文量

198

审稿时长

3.9 months

期刊介绍： The objective of the Journal of Nanoparticle Research is to disseminate knowledge of the physical, chemical and biological phenomena and processes in structures that have at least one lengthscale ranging from molecular to approximately 100 nm (or submicron in some situations), and exhibit improved and novel properties that are a direct result of their small size. Nanoparticle research is a key component of nanoscience, nanoengineering and nanotechnology. The focus of the Journal is on the specific concepts, properties, phenomena, and processes related to particles, tubes, layers, macromolecules, clusters and other finite structures of the nanoscale size range. Synthesis, assembly, transport, reactivity, and stability of such structures are considered. Development of in-situ and ex-situ instrumentation for characterization of nanoparticles and their interfaces should be based on new principles for probing properties and phenomena not well understood at the nanometer scale. Modeling and simulation may include atom-based quantum mechanics; molecular dynamics; single-particle, multi-body and continuum based models; fractals; other methods suitable for modeling particle synthesis, assembling and interaction processes. Realization and application of systems, structures and devices with novel functions obtained via precursor nanoparticles is emphasized. Approaches may include gas-, liquid-, solid-, and vacuum-based processes, size reduction, chemical- and bio-self assembly. Contributions include utilization of nanoparticle systems for enhancing a phenomenon or process and particle assembling into hierarchical structures, as well as formulation and the administration of drugs. Synergistic approaches originating from different disciplines and technologies, and interaction between the research providers and users in this field, are encouraged.